Trial | N | Mean HAQ CFB (SD) | ACR20 Responses | ACR50 Responses | ACR70 Responses |
---|---|---|---|---|---|
Placebo + MTX | |||||
AIM | 219 | −0.40 (0.59) | 87 | 37 | 14 |
Kremer 2005, Kremer 2003 | 119 | −0.14 (0.49*) | 42 | 14 | 2 |
ATTEST | 110 | −0.29 (0.22) | 46 | 22 | 10 |
ARMADA | 62 | −0.27 (0.57) | 9 | 5 | 3 |
DE019 | 200 | −0.24 (0.52) | 59 | 19 | 5 |
RAPID I | 199 | −0.17 (0.56) | 27 | 15 | 6 |
RAPID II | 127 | −0.14 (0.45) | 11 | 4 | 1 |
Weinblatt | 30 | −0.40 (0.49*) | 8 | 1 | 0 |
TEMPO | 228 | −0.63 (1.08*) | 167 | 92 | 34 |
GO-FORWARD | 133 | −0.13 (0.58) | 37 | 18 | 7 |
ATTRACT | 88 | −0.19 (0.49*) | 18 | ||
Abatacept + MTX | |||||
AIM | 433 | −0.59 (0.62) | 294 | 173 | 86 |
Kremer 2005, Kremer 2003 | 115 | −0.42 (0.49*) | 69 | 42 | 19 |
ATTEST | 156 | −0.68 (0.22) | 104 | 63 | 32 |
Adalimumab + MTX | |||||
ARMADA | 67 | −0.62 (0.63) | 45 | 37 | 18 |
DE019 | 207 | −0.56 (0.52) | 131 | 81 | 43 |
Certolizumab + MTX | |||||
RAPID I | 393 | −0.58 (0.59) | 231 | 146 | 84 |
RAPID II | 246 | −0.50 (0.47) | 141 | 80 | 39 |
Etanercept + MTX | |||||
Weinblatt 1999 | 59 | −0.70 (0.49*) | 42 | 23 | 9 |
TEMPO | 231 | −0.89 (1.08*) | 188 | 136 | 82 |
Golimumab + MTX | |||||
GO-FORWARD | 89 | −0.47 (0.55) | 53 | 33 | 18 |
Infliximab + MTX | |||||
ATTEST | 165 | −0.53 (0.29) | 98 | 61 | 40 |
ATTRACT | 86 | −0.31 (0.49*) | 42 |
↵* SD was estimated. MTX: methotrexate.